One complicating issue was the development of gastrointestinal disease symptoms in these mice, which greatly impacted their survival [36]; this was later addressed by development of bitransgenic mice, expressing rat fatty acid binding protein 2 and an intestinal promoter for expression of human CFTR, creating a gut corrected model with increased survival while maintaining lung disease [14]. Here, FABP2 is linked to gastrointestinal disease.